Bio-Techne Corporation (TECH)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. James T. Hippel CPA
|
Executive VP of Finance & CFO | 1.38M | 3.63M | 1971 |
|
Mr. Shane V. Bohnen
|
Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer | 884.35k | 76.27k | 1975 |
|
Mr. William A. Geist
|
President of Protein Sciences Segment | 1.06M | -- | 1969 |
|
Mr. Steven C. Crouse
|
President of Diagnostics & Spatial Biology Segment | 667.96k | -- | 1973 |
|
Dr. Gary J. Latham Ph.D.
|
VP & CTO | -- | -- | -- |
|
Mr. David Clair C.F.A.
|
Vice President of Investor Relations | -- | -- | -- |
|
Mr. Martin Wirtz
|
Senior Vice President of Strategy & Corporate Development | -- | -- | -- |
|
Ms. Cheryl Bethune
|
Senior VP & Chief Human Resources Officer | -- | -- | -- |
|
Mr. Luca Cicchetti
|
Managing Director | -- | -- | -- |
|
Dr. Bernie Andruss
|
Senior Vice President of Bio-Techne Diagnostics Division | -- | -- | -- |
Bio-Techne Corporation
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 3,000
Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Corporate Governance
Upcoming Events
November 9, 2026 at 1:30 PM UTC
Bio-Techne Corporation Earnings Date
Recent Events
September 4, 2026 at 12:00 AM UTC
Dividend Date
August 24, 2026 at 12:00 AM UTC
Ex-Dividend Date
